Multiple Sclerosis Home > Tysabri and Breastfeeding
Although it is known that Tysabri (natalizumab) passes through breast milk, it is not known how much of the drug would pass to the nursing infant or what problems it might cause. This drug is known to cause potentially serious side effects. Due to the potential risks, breastfeeding women should discuss the issues with their healthcare provider before receiving Tysabri.
Can Breastfeeding Women Receive Tysabri?Tysabri® (natalizumab) is a prescription medication approved to slow down the progression of disability and decrease the number of flare-ups (periods of disease relapse) in people with multiple sclerosis. It is also approved to reduce symptoms of moderate-to-severe Crohn's disease.
Tysabri is known to pass through breast milk. If you are nursing a child, talk with your healthcare provider before receiving this medication.
More Information About Tysabri and BreastfeedingThere is little information available on Tysabri and breastfeeding. The manufacturer of the medication states that the drug passes through breast milk. However, it is unknown how much medicine would pass to a nursing infant. The effects of the medication, if any, on a nursing infant are also unknown.
Tysabri is associated with potentially serious side effects, such as infections. Until more research is done, all possible risks cannot be ruled out.
While this lack of information is certainly frustrating, it is important to understand that studies of medications are rarely done in breastfeeding women, as this would usually expose an infant who will not directly benefit from the medication to possible risks from the medication.